Immunopathogenesis of ovarian cancer

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Over 90% of ovarian cancers arise from the surface epithelium, which are classified as epithelial ovarian cancer (EOC). EOCs can be categorized as serous, mucinous, endometrioid, clear cell, and transitional cell types. The molecular pathology of ovarian carcinomas is heterogeneous and involves various putative precursor lesions and multiple pathways of development. Furthermore, in another aspect, immune deficiencies that are present in the ovarian tumor environment enhance the progression of the tumor in the host. The presence of regulatory T cells, the inhibition of natural killer cytotoxic responses, the accumulation of myeloid suppressor cells in the tumor, deficiencies on interferon signaling, the secretion of cytokines that enhance tumor growth (i.e., IL-6, IL-10, CSF-1, TGF-β, TNF), and the expression of surface molecules (i.e., HLA-G, B7-H1, B7-H4, CD40, CD80) that have a role on immune suppression, are discussed in detail. The aim of this review is to provide insight of the evidence that supports the role of immunodeficiency in the progression of ovarian cancer and future directions for ovarian cancer therapies. It also discusses the genetic alterations in the subtypes of ovarian cancers.

Original languageEnglish (US)
Pages (from-to)385-400
Number of pages16
JournalMinerva Medica
Volume100
Issue number5
StatePublished - Oct 1 2009

Fingerprint

Ovarian Neoplasms
Neoplasms
HLA-B7 Antigen
HLA-G Antigens
Macrophage Colony-Stimulating Factor
Molecular Pathology
Regulatory T-Lymphocytes
Myeloid Cells
Interleukin-10
Interferons
Cause of Death
Interleukin-6
Epithelium
Cytokines
Carcinoma
Growth

Keywords

  • Immune diseases
  • Mutation
  • Ovarian neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunopathogenesis of ovarian cancer. / Torres, M. P.; Palanimuthu Ponnusamy, Moorthy; Lakshmanan, I.; Batra, Surinder Kumar.

In: Minerva Medica, Vol. 100, No. 5, 01.10.2009, p. 385-400.

Research output: Contribution to journalReview article

Torres, MP, Palanimuthu Ponnusamy, M, Lakshmanan, I & Batra, SK 2009, 'Immunopathogenesis of ovarian cancer', Minerva Medica, vol. 100, no. 5, pp. 385-400.
Torres, M. P. ; Palanimuthu Ponnusamy, Moorthy ; Lakshmanan, I. ; Batra, Surinder Kumar. / Immunopathogenesis of ovarian cancer. In: Minerva Medica. 2009 ; Vol. 100, No. 5. pp. 385-400.
@article{83e7ee56ca6b4023a02912ae02d3f3ec,
title = "Immunopathogenesis of ovarian cancer",
abstract = "Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Over 90{\%} of ovarian cancers arise from the surface epithelium, which are classified as epithelial ovarian cancer (EOC). EOCs can be categorized as serous, mucinous, endometrioid, clear cell, and transitional cell types. The molecular pathology of ovarian carcinomas is heterogeneous and involves various putative precursor lesions and multiple pathways of development. Furthermore, in another aspect, immune deficiencies that are present in the ovarian tumor environment enhance the progression of the tumor in the host. The presence of regulatory T cells, the inhibition of natural killer cytotoxic responses, the accumulation of myeloid suppressor cells in the tumor, deficiencies on interferon signaling, the secretion of cytokines that enhance tumor growth (i.e., IL-6, IL-10, CSF-1, TGF-β, TNF), and the expression of surface molecules (i.e., HLA-G, B7-H1, B7-H4, CD40, CD80) that have a role on immune suppression, are discussed in detail. The aim of this review is to provide insight of the evidence that supports the role of immunodeficiency in the progression of ovarian cancer and future directions for ovarian cancer therapies. It also discusses the genetic alterations in the subtypes of ovarian cancers.",
keywords = "Immune diseases, Mutation, Ovarian neoplasms",
author = "Torres, {M. P.} and {Palanimuthu Ponnusamy}, Moorthy and I. Lakshmanan and Batra, {Surinder Kumar}",
year = "2009",
month = "10",
day = "1",
language = "English (US)",
volume = "100",
pages = "385--400",
journal = "Minerva Medicolegale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - Immunopathogenesis of ovarian cancer

AU - Torres, M. P.

AU - Palanimuthu Ponnusamy, Moorthy

AU - Lakshmanan, I.

AU - Batra, Surinder Kumar

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Over 90% of ovarian cancers arise from the surface epithelium, which are classified as epithelial ovarian cancer (EOC). EOCs can be categorized as serous, mucinous, endometrioid, clear cell, and transitional cell types. The molecular pathology of ovarian carcinomas is heterogeneous and involves various putative precursor lesions and multiple pathways of development. Furthermore, in another aspect, immune deficiencies that are present in the ovarian tumor environment enhance the progression of the tumor in the host. The presence of regulatory T cells, the inhibition of natural killer cytotoxic responses, the accumulation of myeloid suppressor cells in the tumor, deficiencies on interferon signaling, the secretion of cytokines that enhance tumor growth (i.e., IL-6, IL-10, CSF-1, TGF-β, TNF), and the expression of surface molecules (i.e., HLA-G, B7-H1, B7-H4, CD40, CD80) that have a role on immune suppression, are discussed in detail. The aim of this review is to provide insight of the evidence that supports the role of immunodeficiency in the progression of ovarian cancer and future directions for ovarian cancer therapies. It also discusses the genetic alterations in the subtypes of ovarian cancers.

AB - Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Over 90% of ovarian cancers arise from the surface epithelium, which are classified as epithelial ovarian cancer (EOC). EOCs can be categorized as serous, mucinous, endometrioid, clear cell, and transitional cell types. The molecular pathology of ovarian carcinomas is heterogeneous and involves various putative precursor lesions and multiple pathways of development. Furthermore, in another aspect, immune deficiencies that are present in the ovarian tumor environment enhance the progression of the tumor in the host. The presence of regulatory T cells, the inhibition of natural killer cytotoxic responses, the accumulation of myeloid suppressor cells in the tumor, deficiencies on interferon signaling, the secretion of cytokines that enhance tumor growth (i.e., IL-6, IL-10, CSF-1, TGF-β, TNF), and the expression of surface molecules (i.e., HLA-G, B7-H1, B7-H4, CD40, CD80) that have a role on immune suppression, are discussed in detail. The aim of this review is to provide insight of the evidence that supports the role of immunodeficiency in the progression of ovarian cancer and future directions for ovarian cancer therapies. It also discusses the genetic alterations in the subtypes of ovarian cancers.

KW - Immune diseases

KW - Mutation

KW - Ovarian neoplasms

UR - http://www.scopus.com/inward/record.url?scp=77949534749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949534749&partnerID=8YFLogxK

M3 - Review article

VL - 100

SP - 385

EP - 400

JO - Minerva Medicolegale

JF - Minerva Medicolegale

SN - 0026-4806

IS - 5

ER -